Mark Anderson

This inventor holds 7 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Abbvie Inc., Abbvie Biotherapeutics Inc., Icarus Rt, Inc.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Anderson. Retrieved from https://idiyas.com/inventor/mark-anderson-m4achlbr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 26(Granted Patents)

Location History:

Grayslake, IL (US) (2014 - 2023)
Carlsbad, CA (US) (2024)

Company Filing History:

Abbvie Biotherapeutics Inc.

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12074557 - Hybrid photovoltaic-thermal and co-generation system (2024-08-27),

2. 11633497 - Anti-c-Met antibody drug conjugates (2023-04-25),

3. 10383948 - Anti-cMet antibody drug conjugates and methods for their use (2019-08-20),

4. 10184003 - Prolactin receptor binding proteins and uses thereof (2019-01-22),

5. 10112999 - Anti-PRLR antibody-drug conjugates (ADC) and uses thereof (2018-10-30),

6. 9725515 - Prolactin receptor binding proteins and uses thereof (2017-08-08),

7. 8624027 - Combination therapy for treating cancer and diagnostic assays for use therein (2014-01-07),

Title: Mark Anderson: Innovator in Antibody Drug Conjugates

Introduction

Mark Anderson is a prominent inventor located in Grayslake, IL, whose contributions to the field of biotherapeutics have resulted in an impressive portfolio of six patents. His work primarily focuses on the development of antibody drug conjugates, which are significant in the treatment of cancer and other diseases.

Latest Patents

Among Mark Anderson's latest innovations are two notable patents related to anti-c-Met antibody drug conjugates. The first patent provides c-Met antibody drug conjugates (ADCs), which include various compositions and methods for utilizing these ADCs effectively. The second patent discusses the development of these ADCs that specifically bind to human c-Met, detailing their methods of production and potential uses in treating patients with cancer.

Career Highlights

Mark Anderson has made considerable strides in the biotechnology industry through his tenure at renowned companies such as AbbVie Inc. and AbbVie Biotherapeutics Inc. His work at these organizations has been pivotal in advancing therapeutic approaches that utilize innovative drug delivery systems.

Collaborations

Throughout his career, Mark Anderson has collaborated with esteemed colleagues, such as Edward B. Reilly and Jieyi Wang. These collaborations have further enriched his research and innovation endeavors, contributing to the development of effective therapeutic solutions.

Conclusion

Mark Anderson's contributions to the field of biotherapeutics and his innovative approach to antibody drug conjugates underscore his status as a leading inventor in the industry. With a solid patent portfolio and a commitment to advancing cancer treatment methodologies, Anderson's work continues to impact the scientific community and improve patient outcomes.

Profile summary based on public USPTO records.